IMPACT OF ENDOSCOPIC TREATMENT IN SEVERE DUODENAL POLYPOSIS: A NATIONAL STUDY IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS.

cancer endoscopy familial adenomatous polyposis prevention

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
28 Mar 2024
Historique:
received: 25 10 2023
revised: 06 03 2024
accepted: 07 03 2024
medline: 31 3 2024
pubmed: 31 3 2024
entrez: 30 3 2024
Statut: aheadofprint

Résumé

The majority of patients with Familial Adenomatous Polyposis (FAP) develop duodenal adenomas with a risk of progression to duodenal cancer. Endoscopic management of FAP duodenal adenomas has been proposed as a less invasive option than surgery, but available data are still limited. Our aims were to assess the feasibility and safety of endoscopic treatment in duodenal polyposis and to evaluate its long-term efficacy in terms of recurrence and malignant degeneration. FAP patients with stage IV duodenal polyposis were enrolled in 5 French centers as part of a national cohort and followed for a median period of 5.66 years (IQR 6.39). Primary outcomes were duodenal surgery-free and cancer-free survival. Two groups of patients were identified according to endoscopic procedures: Group 1: resection and or destruction (by argon plasma coagulation) of duodenal polyps and group 2: papillectomy. 58 patients were enrolled (29 men; median age 44 years). Endoscopic therapy was performed in 37 patients of group 1 and 19 of group 2, respectively. Duodenal cancer-free and surgery-free survivals were 95.8% at 5 years and 92.6% at 10 years, respectively. Four patients required surgery and 2 developed cancers. In the 58 patients, the calculated Spigelman score decreased from 9.24 points at entry to 6.35 at five years and then plateaued. Complications (mostly bleeding and perforation) occurred in 20 patients. In this long-term cohort follow up, endoscopic treatment of patients with severe duodenal polyposis appears relatively safe and effective as an alternative to surgery for the prevention of cancer.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The majority of patients with Familial Adenomatous Polyposis (FAP) develop duodenal adenomas with a risk of progression to duodenal cancer. Endoscopic management of FAP duodenal adenomas has been proposed as a less invasive option than surgery, but available data are still limited. Our aims were to assess the feasibility and safety of endoscopic treatment in duodenal polyposis and to evaluate its long-term efficacy in terms of recurrence and malignant degeneration.
METHODS METHODS
FAP patients with stage IV duodenal polyposis were enrolled in 5 French centers as part of a national cohort and followed for a median period of 5.66 years (IQR 6.39). Primary outcomes were duodenal surgery-free and cancer-free survival. Two groups of patients were identified according to endoscopic procedures: Group 1: resection and or destruction (by argon plasma coagulation) of duodenal polyps and group 2: papillectomy.
RESULTS RESULTS
58 patients were enrolled (29 men; median age 44 years). Endoscopic therapy was performed in 37 patients of group 1 and 19 of group 2, respectively. Duodenal cancer-free and surgery-free survivals were 95.8% at 5 years and 92.6% at 10 years, respectively. Four patients required surgery and 2 developed cancers. In the 58 patients, the calculated Spigelman score decreased from 9.24 points at entry to 6.35 at five years and then plateaued. Complications (mostly bleeding and perforation) occurred in 20 patients.
CONCLUSION CONCLUSIONS
In this long-term cohort follow up, endoscopic treatment of patients with severe duodenal polyposis appears relatively safe and effective as an alternative to surgery for the prevention of cancer.

Identifiants

pubmed: 38555039
pii: S1542-3565(24)00289-1
doi: 10.1016/j.cgh.2024.03.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Pierrine Le Bras (P)

Nantes Université, CHU Nantes, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, France.

Estelle Cauchin (E)

Nantes Université, CHU Nantes, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, France.

Glenn De Lange (G)

Medical School, University of Geneva, 1206 Geneva, Switzerland.

Driffa Moussata (D)

Gastroenterology Department, Tours University Hospital, Tours, France.

Géraldine-Anne Garcia (GA)

Gastroenterology Department, University Hospital of Brest, Brest, France.

Lucille Quénéhervé (L)

Gastroenterology Department, University Hospital of Brest, Brest, France.

Jean-Christophe Saurin (JC)

Hôpital E. Herriot, Hospices Civils de Lyon, National reference centre for genetic polyposes, Lyon, France; Department of Gastroenterology and Hepatology, University Hospital of Geneva (HUG), Rue Gabrielle Perret-Gentil 4, 1205 Geneva, Switzerland.

Emmanuel Coron (E)

Nantes Université, CHU Nantes, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, France. Electronic address: emmanuel.coron@hcuge.ch.

Classifications MeSH